Product Images Clopidogrel

This text contains information about Clopidogrel tablets with a dosage of 75 mg and a quantity of 90 tablets. It provides details such as the NDC number, manufacturer (Ascend Labs, LLC), storage instructions, and dosage recommendation. The medication is repackaged by RemedyRepack Inc. and is intended for prescription-only use.*

This text provides data on the cumulative event rate for cardiovascular death, myocardial infarction, and stroke for patients taking placebo with aspirin versus clopidogrel with aspirin over a specific follow-up period. The data suggests a statistically significant difference between the two groups, with a p-value of 0.00009. The study also mentions the use of other standard therapies during the trial.*

This text appears to contain information regarding the administration of medications such as Heparin/LMWH, Aspirin, GPIIb/la Antag, Beta-Blocker, and Ace Inhibitor, as well as the previous medical history of patients including MI and stroke. Additionally, it provides statistical data on the usage of Clopidogrel and Placebo in different groups. These details could be part of a research study or clinical trial evaluating the effectiveness of these medications in patients with a history of cardiovascular events.*

This text provides information on the cumulative event rates for fatal or non-fatal vascular events over time for patients treated with aspirin and clopidogrel. The data shows the event rates at different time points (6, 12, 18, 24, and 30 months) of follow-up. The P-value of 0.045 indicates a statistically significant difference between the two treatments.*

The text provided describes the comparison of mortality rates between a placebo group and a group receiving Clopidogrel tablets. The data shows 1845 deaths (8.1%) in the placebo group and 1726 deaths (7.5%) in the group receiving Clopidogrel tablets. There is a 7% proportional risk reduction associated with Clopidogrel tablets with a p-value of 0.03. The study was conducted over 28 days with all treated patients also receiving aspirin.*

This description provides data on the comparison between a placebo and Clopidrogel Tablets in reducing the risk of death, reinfarction, or stroke before discharge. The study reveals a 9% proportional risk reduction with Clopidrogel Tablets compared to the placebo group, with statistical significance (p=0.002). The graph displays the progression of events over 28 days since randomization, with all treated patients also receiving aspirin.*

This is a statistical data table showing detailed information about a subgroup analysis related to gender, age, hours since onset, vital signs like systolic blood pressure and heart rate, use of fibrinolytic agents, and treatment with Clopidogrel tablets and Placebo in a study. The table presents the number of cases in different categories and corresponding percentages, allowing for comparisons and analyses.*

The provided text includes data on the number and percentage of patients taking Clopidogrel tablets and Aspirin in relation to stroke and PAD conditions. It also mentions hazard ratios with corresponding confidence intervals. The information seems to be part of a study or report evaluating the efficacy of these medications in specific conditions.*